ExploreWatchlistsPricing
  1. JP-listed companies
  2. AnGes, Inc.
  3. Financials
  4. Operating margin (%)

AnGes, Inc. (4563)

Market cap
¥22.6B
P/E ratio
-2.2x
AnGes develops gene medicines and nucleic acid treatments, while providing genetic screening tests for rare disorders through its clinical research laboratory.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating margin (%) YoY (%)
Dec 31, 2025-588.6-58.41%
Dec 31, 2024-1,415.3-81.91%
Dec 31, 2023-7,822.7-67.85%
Dec 31, 2022-24,331.3-0.15%
Dec 31, 2021-24,368.8+74.07%
Dec 31, 2020-13,999.2+1298.88%
Dec 31, 2019-1,000.7+99.17%
Dec 31, 2018-502.5-44.21%
Dec 31, 2017-900.6-2.77%
Dec 31, 2016-926.2-4.50%
Dec 31, 2015-969.9+288.11%
Dec 31, 2014-249.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat